CANF – can-fite biopharma ltd sponsored adr (israel) (US:NASDAQ)
Stock Stats
News
Can-Fite BioPharma Ltd. (NYSE: CANF) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia [Yahoo! Finance]
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
Can-Fite BioPharma Ltd. (NYSE: CANF) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Form 6-K Can-Fite BioPharma Ltd. For: Nov 11
Form 6-K Can-Fite BioPharma Ltd. For: Nov 04
Form 6-K Can-Fite BioPharma Ltd. For: Oct 18
Form 6-K Can-Fite BioPharma Ltd. For: Oct 09
Form 6-K Can-Fite BioPharma Ltd. For: Sep 24
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.